Clinical Trial Update: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Tazemetostat in combination with Lenalidomide and Rituximab versus placebo with Lenalidomide and Rituximab in adults with relapsed/re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Or Refractory Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING